Samil Pharmaceutical Co.,Ltd (000520.KS)
KRW 13130.0
(-3.95%)
KRW 13130.0
(-3.95%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 196.34 Billion KRW | 9.28% |
| 2022 | 179.67 Billion KRW | 33.84% |
| 2021 | 134.24 Billion KRW | 9.14% |
| 2020 | 122.99 Billion KRW | 1.56% |
| 2019 | 121.1 Billion KRW | 28.02% |
| 2018 | 94.59 Billion KRW | 2.78% |
| 2017 | 92.03 Billion KRW | -4.88% |
| 2016 | 96.75 Billion KRW | 9.78% |
| 2015 | 88.13 Billion KRW | 3.13% |
| 2014 | 85.46 Billion KRW | -4.22% |
| 2013 | 89.22 Billion KRW | -2.42% |
| 2012 | 91.44 Billion KRW | -3.21% |
| 2011 | 94.47 Billion KRW | -3.92% |
| 2010 | 98.33 Billion KRW | -15.19% |
| 2009 | 115.94 Billion KRW | -7.62% |
| 2008 | 125.51 Billion KRW | 19.65% |
| 2007 | 104.9 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 54.28 Billion KRW | -0.02% |
| 2024 Q1 | 54.29 Billion KRW | 7.49% |
| 2023 FY | 196.34 Billion KRW | 9.28% |
| 2023 Q4 | 50.51 Billion KRW | -2.16% |
| 2023 Q2 | 48.46 Billion KRW | 5.95% |
| 2023 Q1 | 45.73 Billion KRW | 5.24% |
| 2023 Q3 | 51.63 Billion KRW | 6.54% |
| 2022 Q4 | 43.46 Billion KRW | -4.26% |
| 2022 FY | 179.67 Billion KRW | 33.84% |
| 2022 Q2 | 44.96 Billion KRW | -1.93% |
| 2022 Q3 | 45.39 Billion KRW | 0.96% |
| 2022 Q1 | 45.85 Billion KRW | 33.69% |
| 2021 Q2 | 33.93 Billion KRW | 5.32% |
| 2021 Q3 | 33.79 Billion KRW | -0.4% |
| 2021 Q1 | 32.22 Billion KRW | 7.32% |
| 2021 FY | 134.24 Billion KRW | 9.14% |
| 2021 Q4 | 34.29 Billion KRW | 1.48% |
| 2020 Q3 | 31.11 Billion KRW | 5.68% |
| 2020 FY | 122.99 Billion KRW | 1.56% |
| 2020 Q1 | 32.42 Billion KRW | 7.59% |
| 2020 Q2 | 29.43 Billion KRW | -9.21% |
| 2020 Q4 | 30.02 Billion KRW | -3.5% |
| 2019 Q3 | 30.3 Billion KRW | 0.24% |
| 2019 Q4 | 30.13 Billion KRW | -0.55% |
| 2019 Q2 | 30.23 Billion KRW | -0.65% |
| 2019 Q1 | 30.43 Billion KRW | 30.08% |
| 2019 FY | 121.1 Billion KRW | 28.02% |
| 2018 Q3 | 23.79 Billion KRW | -5.5% |
| 2018 FY | 94.59 Billion KRW | 2.78% |
| 2018 Q4 | 23.39 Billion KRW | -1.69% |
| 2018 Q2 | 25.18 Billion KRW | 13.29% |
| 2018 Q1 | 22.22 Billion KRW | -13.44% |
| 2017 FY | 92.03 Billion KRW | -4.88% |
| 2017 Q3 | 21.83 Billion KRW | -3.2% |
| 2017 Q4 | 25.67 Billion KRW | 17.62% |
| 2017 Q2 | 22.55 Billion KRW | 2.61% |
| 2017 Q1 | 21.97 Billion KRW | -9.55% |
| 2016 Q1 | 24.05 Billion KRW | 11.6% |
| 2016 Q4 | 24.29 Billion KRW | 4.32% |
| 2016 FY | 96.75 Billion KRW | 9.78% |
| 2016 Q3 | 23.29 Billion KRW | -7.28% |
| 2016 Q2 | 25.11 Billion KRW | 4.45% |
| 2015 Q1 | 23.53 Billion KRW | 22.5% |
| 2015 Q4 | 21.54 Billion KRW | -1.62% |
| 2015 Q3 | 21.9 Billion KRW | 3.57% |
| 2015 Q2 | 21.15 Billion KRW | -10.11% |
| 2015 FY | 88.13 Billion KRW | 3.13% |
| 2014 Q3 | 21.54 Billion KRW | -0.06% |
| 2014 Q4 | 19.2 Billion KRW | -10.86% |
| 2014 FY | 85.46 Billion KRW | -4.22% |
| 2014 Q1 | 23.14 Billion KRW | 7.98% |
| 2014 Q2 | 21.56 Billion KRW | -6.83% |
| 2013 Q4 | 21.43 Billion KRW | 0.09% |
| 2013 Q1 | 23.16 Billion KRW | 4.37% |
| 2013 Q2 | 23.22 Billion KRW | 0.25% |
| 2013 FY | 89.22 Billion KRW | -2.42% |
| 2013 Q3 | 21.41 Billion KRW | -7.8% |
| 2012 Q3 | 22.65 Billion KRW | -10.83% |
| 2012 Q4 | 22.19 Billion KRW | -2.02% |
| 2012 FY | 91.44 Billion KRW | -3.21% |
| 2012 Q1 | 20.51 Billion KRW | 0.0% |
| 2012 Q2 | 25.4 Billion KRW | 23.85% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 94.47 Billion KRW | -3.92% |
| 2011 Q3 | 23.5 Billion KRW | -7.76% |
| 2011 Q2 | 25.48 Billion KRW | 3.76% |
| 2011 Q1 | 24.55 Billion KRW | 4.29% |
| 2010 FY | 98.33 Billion KRW | -15.19% |
| 2010 Q3 | 23.93 Billion KRW | -12.92% |
| 2010 Q4 | 23.54 Billion KRW | -1.6% |
| 2010 Q2 | 27.48 Billion KRW | 17.6% |
| 2010 Q1 | 23.37 Billion KRW | -23.69% |
| 2009 Q4 | 30.62 Billion KRW | 3.2% |
| 2009 Q1 | 27.16 Billion KRW | 9.43% |
| 2009 Q3 | 29.67 Billion KRW | 4.17% |
| 2009 Q2 | 28.48 Billion KRW | 4.89% |
| 2009 FY | 115.94 Billion KRW | -7.62% |
| 2008 Q1 | 34.19 Billion KRW | 42.86% |
| 2008 Q3 | 30.14 Billion KRW | -17.07% |
| 2008 FY | 125.51 Billion KRW | 19.65% |
| 2008 Q2 | 36.35 Billion KRW | 6.31% |
| 2008 Q4 | 24.81 Billion KRW | -17.68% |
| 2007 Q1 | 26.74 Billion KRW | 0.0% |
| 2007 Q2 | 27.64 Billion KRW | 3.38% |
| 2007 Q3 | 26.57 Billion KRW | -3.89% |
| 2007 FY | 104.9 Billion KRW | 0.0% |
| 2007 Q4 | 23.93 Billion KRW | -9.92% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -43.099% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 82.655% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 69.246% |
| HANDOK Inc. | 522.74 Billion KRW | 62.439% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -45.041% |
| Yuhan Corporation | 1858.98 Billion KRW | 89.438% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 70.429% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -277.915% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 86.83% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -45.539% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 47.011% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -121.625% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -15.792% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 12.524% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -43.099% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -151.554% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -29.969% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -124.745% |
| JW Holdings Corporation | 928.07 Billion KRW | 78.844% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 67.317% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 88.239% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 73.769% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 1.939% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -8.621% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 72.97% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -43.099% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 87.035% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 85.724% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 73.769% |
| Yuhan Corporation | 1858.98 Billion KRW | 89.438% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 75.294% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 16.414% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 66.977% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 73.769% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 32.788% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 29.611% |
| CKD Bio Corp. | 160.35 Billion KRW | -22.446% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 62.739% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 45.627% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 14.778% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 1.939% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 77.682% |
| Boryung Corporation | 859.62 Billion KRW | 77.159% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -55.919% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 47.011% |
| JW Lifescience Corporation | 206.86 Billion KRW | 5.083% |